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Abstract. Alzheimer’s disease (AD) is a neurodegenerative disorder represented by the accumulation of intracellular tau
protein and extracellular deposits of amyloid- (A) in the brain. The gene sortilin 1 (SORT1) has previously been associated
with cardiovascular disease in gene association studies. It has also been proposed to be involved in AD pathogenesis through
facilitating A clearance by binding apoE/A complexes prior to cellular uptake. However, the neuropathological role of
SORT1 in AD is not fully understood. To evaluate the associations between gene variants of SORT1 and risk of AD, we
performed genetic analyses in a Swedish case-control cohort. Ten single nucleotide polymorphisms (SNPs), covering the
whole SORT1 gene, were selected and genotyped in 620 AD patients and 1107 controls. The SNP rs17646665, located in
a non-coding region of the SORT1 gene, remained significantly associated with decreased risk of AD after multiple testing
(pc = 0.0061). In addition, other SNPs were found to be nominally associated with risk of AD, as well as altered cognitive
function and the CSF biomarker A42, but these associations did not survive correction for multiple testing. The fact that
SORT1 has been strongly associated with risk of cardiovascular disease is intriguing as cardiovascular disease is also regarded
as a risk factor for AD. Finally, increased knowledge about SORT1 function has a potential to increase our understanding of
APOE, the strongest risk factor for AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative
disorder and the most predominant form of dementia
in the elderly population, with a prevalence of 10%
in adults older than 65 years of age [1]. The disease
is characterized by a gradual synaptic and neuronal
loss that causes cognitive impairment with gradual
progression into severe dementia with a terminal out-
come. The histopathological hallmarks of AD include
the accumulation of intracellular neurofibrillary tan-
gles composed of hyperphosphorylated protein tau
(P-tau) and extracellular deposits of amyloid- (A)
in the brain of AD patients [1]. Today, a genetic back-
ground can partly explain the incidence of early-onset
AD, also called familial AD (fAD), where the genes
involved in A production and processing contain
mutations, namely amyloid precursor protein (APP),
presenilin 1 (PSEN1), and presenilin 2 (PSEN2)
[2].
For late-onset, sporadic AD (sAD), which is the
predominant form of AD, the APOE 4 allele has
been shown to be the major genetic risk factor [3, 4].
ApoE is mainly produced by astrocytes and microglia
in the central nervous system [5] where it delivers
peptides to neurons for synaptic maintenance [6].
With regard to AD, the role of apoE is not fully under-
stood. Although some evidence shows that apoE can
bind to A and facilitate cellular uptake of the pep-
tide from the extracellular space into endosomes for
catabolism [7, 8], the underlying molecular mecha-
nisms are still unclear.
Sortilin 1 (referred to as sortilin here), is a trans-
membrane sorting receptor encoded by the SORT1
gene. Sortilin is expressed both in neurons and non-
neuronal cells and was first discovered in a screen
for endocytic receptors [9]. In the brain, high lev-
els of sortilin expression and immunoreactivity have
been found in neuronal cell bodies and dendrites of
allocortical areas such as the piriform cortex and hip-
pocampus [10]. Sortilin was initially recognized as
an intracellular transporter located in the trans-Golgi
network [11], showing high similarities to the sort-
ing receptor VPS10P in Saccharomyces cerevisiae
[12]. The VPS10P domain of sortilin encompasses
the extracellular part of the protein [13] and is shared
among receptors in the VPS10P domain receptor fam-
ily [14]. Sortilin is involved in complex trafficking
patterns in which it can relocate from the cell surface
and bind unrelated ligands, mediating transport to
various cellular compartments including endosomes
and lysosomes [15].
With regard to AD, sortilin has been proposed
to be involved in the pathogenesis through several,
sometimes contradictory, mechanisms. In cell stud-
ies, sortilin facilitates retrograde trafficking of the
APP-cleaving enzyme beta secretase-1 (BACE-1)
to Golgi and increases the cleavage of APP, stimu-
lating A production [16, 17]. Also, oligomerized A
has been shown to act as a ligand for sortilin, inducing
endocytosis of A and apoptosis [18]. Additionally,
other experiments have revealed that sortilin also
binds to and targets APP for lysosomal degradation,
as well as promotes -secretase cleavage of APP
[19]. Studies in rodents demonstrate that sortilin is
capable of binding extracellular apoE/A complexes
delivering them to lysosomes for degradation. Hence,
rodents lacking the sortilin gene displayed increased
apoE levels and A plaque burden [20]. Furthermore,
a significant increase in sortilin protein levels has
been observed in postmortem brains has of patients
with AD [21].
Single nucleotide polymorphisms (SNPs) within
and in the vicinity of the SORT1 gene have previously
been associated with cardiovascular diseases (CVD)
[22–27] and serum LDL levels [25, 28–33]. Also,
altered SORT1 mRNA expression [34] and increased
serum levels of sortilin has been found in patients
suffering from depression, where two SNPs within
SORT1 were significantly associated with increased
serum levels of the protein [35].
Gene association studies have highlighted sortilin-
related receptor 1 (SORL1), another member of the
VPS10P domain receptor family, as a candidate gene
for AD [36]. According to AlzGene [37], a database
collecting published genetic association data in AD
patients, no studies so far have shown any signifi-
cant associations between gene variants of SORT1
and the risk of developing AD. However, since pre-
clinical findings indicate promising functional roles
for sortilin in AD pathogenesis, we were intrigued
to test whether SORT1 was associated with AD in
a clinical AD material. In the present study we
report a case-control association study of SORT1 in a
Swedish cohort of AD patients and controls of Cau-
casian descent. The genetic variation in SORT1 was
tested against diagnosis, mini-mental state examina-
tion (MMSE) and characteristic cerebrospinal fluid
(CSF) biomarkers for AD, i.e., total tau (T-tau), P-tau,
and A42.
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MATERIALS AND METHODS
Study cohort
The Swedish case-control study population con-
sisted of 620 AD patients and 1,107 controls of
Caucasian origin. AD patients were recruited from
Pitea˚ (n = 182) and Malmo¨ (n = 438), whereas con-
trol patients were recruited from Malmo¨ (n = 433)
and Gothenburg (Mo¨lndal) (n = 674). Demograph-
ics for the participants are found in Table 1.
All diagnoses were set according to the National
Institute of Neurological and Communicative Dis-
orders and Stroke-Alzheimer’s Disease and Related
Disorders (NINCDS-ADRDA) criteria [38] follow-
ing detailed clinical investigation including medical
history, physical, neurological and psychiatric exami-
nation, screening laboratory tests, ECG, chest X-rays,
EEG, and computerized tomography (CT) of the
brain. No patient had a family history raising sus-
picion of familial AD, but PSEN1, PSEN2, and
APP genes were not sequenced. Controls had no
dementia and showed no signs of other psychiatric
or neurological disorders including stroke, malig-
nant disorders or infectious diseases. Controls with a
Mini-Mental State Examination (MMSE) score lower
than 28 were excluded from the study to reduce the
risk of including controls with potential of devel-
oping AD. MMSE score data were available for
568 AD patients and 837 controls and were tested
according to Folstein et al. [39]. The APOE 4 car-
rier status is presented in Table 1. Quantifications
of AD-related CSF biomarkers (T-tau, P-tau, and
A42) were available for a subset of the AD patients
(T-tau n = 493, P-tau n = 266, and A42 n = 481).
The diagnosis was set without prior knowledge of
genetic background or biochemical analysis and vice
versa.
Genotyping and DNA preparation
The sequence of SORT1 (Gene ID: 6272) was
obtained from the UCSC Genome Browser, assem-
bly GRCh38/hg38 [40] and the HapMap project [41].
The software Haploview 4.2 was used to create a link-
age disequilibrium (LD) block and to identify genetic
variation (tag SNPs) in the gene. The TAGGER func-
tion in Haploview was used to select tag SNPs with
the criteria of a minor allele frequency (MAF) ≥0.05
and a pairwise tagging was set to r2 = 0.8.
Table 1
Demographics for Alzheimer’s disease (AD) cases and controls
Parameter AD Control p
Number of subjects n 620 1107
Age1 years 75.4 ± 7.3 71.8 ± 5.6 <0.001
Sex male 243 (39.5) 372 (33.7) <0.05
female 372 (60.5) 733 (66.3)
MMSE2 20 ± 5.6 29 ± 0.8 <0.001
Number of 0 186 (30.3) 774 (70.2)
APOE 4 1 317 (51.6) 298 (27.0) <0.001
alleles 2 111 (18.1) 31 (2.8)
Data are presented as absolute numbers with percentages in
parentheses or as mean ± SD. P-values for categorical variables
were calculated using chi-square statistical test and p-values for
continuous variables were calculated using t-test. 1nAD = 614;
nControl = 1104. 2nAD = 568; nControl = 837.
Fig. 1. Linkage disequilibrium (LD) plot for the ten selected SNPs
within and in the vicinity of the SORT1 gene. The correlation
between SNPs is shown by their pairwise r2 values indicated by
numbers and greyscale. The plot was generated using Haploview
software from the genotyping data in the cohort.
A regional linkage disequilibrium (LD) plot was
created for the SNP rs17646665 using SNAP soft-
ware [42], to localize SNPs in the vicinity of rs176
46665 which are in LD. The plot was created using the
parameters: 1000 Genomes Pilot 1 dataset, CEU pop-
ulation panel, r2 threshold set to 0.8 with a distance
limit of 500.
In total, nine tag SNPs were chosen to fully cover
the SORT1 gene, forming one LD block (Fig. 1).
In addition, the SNP rs646776 was also included in
the study since it has been shown to regulate the
expression of SORT1 [28, 43] and has previously
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been associated with LDL serum levels as well as
cardiovascular implications [28, 43].
Genomic DNA was extracted from whole blood
using GenoPrep™ DNA Blood and DNA Mag-
Attract kit (Qiagen, Germany), together with the
GenoMTM-48 Robotic Workstation (GenoVision,
Norway) and stored in –20◦C until it was used for
analysis. Samples were sent to LGC Genomics [44]
for sequencing using a KASP™ genotyping assay.
Cerebrospinal ﬂuid analysis
Studies have shown that AD patients have
decreased levels of A42 and increased levels of T-
tau and P-tau in CSF compared with controls [45].
Levels of T-tau, P-tau, and A42 were therefore
measured and used as biochemical markers in this
study [46, 47]. CSF samples were obtained from
AD patients by lumbar puncture in the L3/L4 or
L4/L5 interspace as previously described [48]. T-tau
and P-tau were determined using a sandwich ELISA
(Innotest™ hTAU-Ag, Fujirebio, Ghent, Belgium)
[46] and A42 levels were also measured in a sand-
wich ELISA (Innotest -amyloid (1-42), Fujirebio,
Ghent, Belgium) specifically constructed for A42
as described previously [47].
Statistical analyses
Controls and AD patients were compared using
t-test for continuous parameters (MMSE, age, and
CSF biomarkers) whereas Pearson chi-square test
was used when categorical parameters (APOE 4
carrier status and sex) were analyzed. All SNPs
were tested for deviation from Hardy-Weinberg
equilibrium (HWE). SNP association to diagnosis
was performed using logistic regression with an
additive genetic model with sex and number of
APOE 4 alleles as covariates. Single marker asso-
ciations to continuous parameters (MMSE and CSF
biomarkers) were only performed in the AD patient
group and analyzed using linear regression with sex,
age, and number of APOE 4 alleles as covariates.
P-values <0.05 were considered statistically signifi-
cant. A permutation test (set to 10 000 permutations)
was performed for all SNPs to correct for multiple
testing. Haplotype analyses were performed using
a window size of 2-3. The statistical analyses in this
study were carried out using IBM SPSS Statistics
version 20, (New York, NY, USA) and Plink v1.07
[49].
Ethics
The clinical evaluation of all study participants
was set without any prior knowledge of genetic back-
ground or any other biochemical analysis results, and
vice versa. Participants (or their close relatives) gave
their consent for participating in the study as well as
for future results being published, which was directed
in accordance with the provisions of the Helsinki
Declaration. This study was approved by the ethical
committees in Lund, Gothenburg and Umea˚.
RESULTS
In this study, a total of 1727 samples were ana-
lyzed, including 620 AD patients and 1107 controls
of Swedish, Caucasian descent (Table 1). When back-
ground parameters were compared, APOE 4 allele
frequencies, sex, age, and MMSE were shown to dif-
fer between AD cases and controls. In the case of
APOE 4 and MMSE, our results are expected and
in line with prior knowledge that AD patients carry
the APOE 4 allele more frequently and show lower
MMSE scores. Regarding distribution differences in
sex, a portion of the controls were recruited from a
longitudinal population study of female participants
which explains the skewed ratio.
We selected nine SNPs to cover the full SORT1
gene, and also included a SNP located downstream
of SORT1 (Table 2 and Fig. 1), which has shown a
strong association with LDL serum levels [25, 28,
30, 31, 33]. The genotyping of SORT1 generated an
average call rate of 98.4% for all selected SNPs in
Table 2
Summary of SORT1 SNPs studied
SNP Genomic Alleles MAF SNP
position (%) location
SORT1 Chromosome 1 minor:major
rs646776 109275908 C:T 23.6 Near gene 3’
rs464218 109313684 G:A 46.5 3’UTR
rs17585355 109315193 C:A 6.3 Intron
rs11102972 109338099 C:T 23.0 Intron
rs7536292 109352071 C:T 17.4 Intron
rs11142 109354481 A:G 30.2 Coding syn.
rs17646665 109369429 G:A 6.9 Intron
rs1149175 109379755 A:G 14.5 Intron
rs12037569 109381055 T:G 15.2 Intron
rs72646553 109397881 C:G 22.4 Coding syn.
Presented are single-nucleotide polymorphisms (SNPs) numbered
according to the gene location. Genome positions were obtained
from the NCBI genome database. MAF, minor allele frequency,
presented as percentages for each SNP. UTR, untranslated region.
Coding syn., Coding synonymous.
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this study. Genotype frequencies were in agreement
with HWE for both AD patients and controls. The
MAFs ranged from 0.063 to 0.47 which was in the
same range as the published HapMap data for the
same SNPs in other Caucasian cohorts [41].
Next, we used the genotyping data to investigate
possible associations between SORT1 and the risk
of AD (Table 3). When only the SNPs in SORT1
were used in the calculations for association to AD,
i.e., without any covariates in the analysis, the SNPs
rs17646665 (p = 0.0034) and rs72646553 (p = 0.014)
were both nominally associated with a reduced risk
for AD. When the identified covariates for this pop-
ulation (sex and number of APOE 4 alleles) were
included in the analysis, rs72646553 was no longer
significantly associated with diagnosis (padj = 0.052)
(Table 3). However, rs17646665 remained strongly
significantly (padj = 0.00063) associated with risk of
AD (Table 3). The association also survived a multi-
ple testing correction (pc = 0.0061).
Since the patients originated from different regions
in Sweden, there is a risk that the association would
be the result of regional genetic differences. To
evaluate this possibility, we performed an analysis
of rs17646665 in the Malmo¨/Lund population only
where both controls and AD patients were available.
This analysis showed the same association with risk
of AD (ORadj (95% CI) = 0.5 (0.3–0.8); padj = 0.0015)
as our analysis of the whole population. This indicates
that the association was not due to regional genetic
differences in the populations studied. A haplotype
analysis was also performed although the significant
associations found did not add anything beyond the
association of the SNP associated with the disease,
rs17646665.
To further investigate genes that could be related to
our gene variant of SORT1, we created a regional LD
plot from available CEU population panel data for
rs17646665 to localize SNPs in its vicinity, which
are in LD (Fig. 2). According to the regional LD plot,
it is clear that no other SNP within the SORT1 gene
are in strong LD with rs17646665. In total, six SNPs
were identified (r2 > 0.8) and localized in or near
the genes synaptophysin-like 2 (SYPL2; rs2272272),
adhesion molecule with Ig-like domain 1 (AMIGO1;
rs17575427), 5’ of G protein-coupled receptor 61
(GPR61; rs552101), between AMIGO1 and GPR61
(rs56018934), guanine nucleotide binding protein
(G protein), alpha inhibiting activity polypeptide 3
(GNAI3; rs1279195) and glutathione S-transferase
mu 4 (GSTM4; rs650985). This indicates that these
SNPs are also likely to be associated with risk of AD.
Finally, all SNPs in this study were also ana-
lyzed in relation to MMSE scores and levels of CSF
biomarkers T-tau, P-tau, and A42 in the AD patients.
For MMSE, the minor allele of rs7536292 (adjusted
slope (adj) = 0.85, padj = 0.044) was nominally
significantly associated with a higher MMSE score,
although the results did not survive a multiple testing
correction (pc = 0.26).
In the case of A42, the two SNPs rs646776
(adj = 26.60, padj = 0.031) and rs72646553 (adj =
–33.07, padj = 0.010) were both nominally associ-
ated with altered levels of this biomarker. The minor
allele of rs646776 was associated with higher lev-
els of A42, whereas rs72646553 showed a reverse
trend, with a minor allele associated with lower
A42 levels. These associations were however not
significant after a correction (rs646776 pc = 0.20;
rs72646553 pc = 0.082). Regarding T-tau and P-tau,
no SNPs were found to be associated with levels of the
two biomarkers. A haplotype analysis was also per-
formed, but no significant associations were found.
DISCUSSION
The main objective of this study was to investigate
possible associations between variants of the SORT1
gene and the risk of AD. In addition, in the AD cohort,
the SNPs were also tested for associations to the AD
CSF biomarker levels, as well as MMSE scores, with
the latter serving as a measure for cognitive function.
To this end, SNPs selected in this study consisted
of both new tag SNPs as well as SNPs previously
investigated for association to AD or other diseases
(Table 2). Our results showed that the minor allele of
rs17646665 was strongly associated (padj = 0.00063;
pc = 0.0061) with a reduced risk of AD. The asso-
ciation thus remained significant after adjusting for
relevant covariates (sex and number of APOE 4 alle-
les) and correcting for multiple testing. To evaluate
this association further, future replications in Swedish
and other populations are warranted.
As the SNP rs17646665 has not previously been
associated with any disease, we were interested in
studying it further. According to the regional LD
plot created for rs17646665 (Fig. 2), it is clear
that no other SNPs within the SORT1 gene are in
LD with rs17646665. The six SNPs in LD with
rs17646665 were localized in or near the genes
SYPL2 (rs2272272), AMIGO1 (rs17575427), 5’ of
GPR61 (rs552101), between AMIGO1 and GPR61
(rs56018934), GNAI3 (rs1279195) and GSTM4
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Table 3
SORT1 single marker (SNP) frequencies and associations with risk of Alzheimer’s disease
SNP Genotype AD (%) Control (%) ORadj (95% CI) padj
rs646776 CC 27 (4.4) 70 (6.4)
CT 221 (36.2) 388 (35.5) 1.0 (0.8–1.2) 0.81
TT 362 (59.3) 636 (58.1)
rs464218 GG 124 (20.3) 254 (23.1)
GA 308 (50.5) 527 (47.9) 1.0 (0.8–1.2) 0.88
AA 178 (29.2) 319 (29.0)
rs17585355 CC 2 (0.3) 3 (0.3)
CA 64 (10.4) 142 (12.9) 0.8 (0.6–1.2) 0.27
AA 552 (89.3) 952 (86.8)
rs11102972 CC 33 (5.5) 59 (5.4)
CT 192 (31.7) 405 (37.2) 0.9 (0.7–1.1) 0.15
TT 380 (62.8) 626 (57.4)
rs7536292 CC 23 (3.8) 30 (2.7)
CT 177 (29.0) 311 (28.3) 1.2 (0.9–1.4) 0.17
TT 410 (67.2) 757 (68.9)
rs11142 AA 50 (8.3) 99 (9.3)
AG 239 (39.8) 466 (44.0) 0.9 (0.7–1.1) 0.17
GG 311 (51.8) 494 (46.6)
rs17646665 GG 0 (0.0) 7 (0.6)
GA 64 (10.5) 159 (14.5) 0.6 (0.4–0.8) 0.00063
AA 547 (89.5) 930 (84.9)
rs1149175 AA 17 (2.8) 25 (2.3)
AG 133 (21.6) 279 (25.4) 0.9 (0.7–1.1) 0.35
GG 466 (75.6) 796 (72.4)
rs12037569 TT 14 (2.3) 24 (2.2)
TG 158 (25.9) 285 (26.0) 1.0 (0.8–1.3) 0.75
GG 437 (71.8) 786 (71.8)
rs72646553 CC 33 (5.6) 58 (5.4)
CG 169 (28.7) 398 (36.7) 0.8 (0.7–1.0) 0.05
GG 386 (65.6) 628 (57.9)
Genotype data are presented as absolute numbers (percentages). OR, odds ratio per minor allele; CI, confidence
interval; ORadj, adjusted odds ratio; padj, adjusted p-value using covariates. P-values were calculated using a logistic
regression model adjusted for sex and number of APOE 4 alleles. Bold numbers indicate p-values <0.05.
(rs650985). This indicates that variants in these genes
have the potential to be involved in the pathogenesis
of AD. Interestingly, AMIGO1 has been shown to
be involved in both neuronal development and sur-
vival, with a potential correlation to A42 [50, 51].
In addition, analysis of rs17646665 in Genotype-
Tissue Expression (GTEx) databases at the GTEx
Portal [52] revealed that this SNP is associated with
reduced SYPL2 expression in many different tissues.
Moreover, SYPL2 (also known as mitsugumin 29)
expression has been identified in astrocytes around
A plaques in AD brains [53].
For AD patients, genetic variations in SORT1 were
also investigated with regard to characteristic AD
CSF biomarkers, namely T-tau, P-tau and A42, as
well as MMSE scores. While rs17646665, which was
associated with risk of AD, showed no significant
association to any of the CSF biomarkers, rs646776
and rs72646553 were nominally associated with CSF
levels of A42. The two SNPs had different effects on
A42 levels, with the minor allele of rs646776 being
associated with increased CSF A42 levels, whilst
the minor allele of rs72646553 caused an opposing
outcome. This is in line with the LD pattern between
the two SNPs.
The SNP rs646776 is located in a non-coding
DNA region in-between the genes cadherin EGF
LAG seven-pass G-type receptor 2 (CELSR2) and
proline and serine rich coiled-coil 1 (PSRC1), where
the minor allele has been associated with increase
in expression of SORT1 [43]. This is in agreement
with the hypothesis that increased sortilin levels are
protective against A42 accumulation by facilitating
uptake and degradation of apoE/A complexes [20],
as increased CSF levels of A42 correspond to lower
A42 aggregation in the brain [47].
The SNP rs72646553 is localized in the first exon
of SORT1 where the genetic variation generates a
synonymous mutation. Data from the GTEx portal
indicate that the minor allele is associated with a
slight increase in expression of SORT1 that could
affect A42 metabolism. However, in the present
C.-H. Andersson et al. / SORT1 is Associated with Alzheimer’s Disease 1359
Fig. 2. The regional LD plot was created from a published CEU population panel for rs17646665, located in SORT1 (marked by the arrow)
with 500 kb flanking genomic regions on each side. The r2 threshold was set to 0.8 and six SNPs were identified with r2 > 0.8 for this region,
all of which were located in other genes than SORT1. The SNPs are indicated by the numbers over the boxes (1: SYPL2 (rs2272272), 2:
AMIGO1 (rs17575427), 3: 5’ of GPR61 (rs552101), 4: between AMIGO1 and GPR61 (rs56018934), 5: GNAI3 (rs1279195) and 6: GSTM4
(rs650985)).
study, rs72646553 was both nominally associated
with decreased A42 CSF levels, indicative of AD,
but it was also nominally associated with reduced
risk of AD. It is therefore difficult to draw any con-
clusions from this finding. Although the results were
nominally significant, neither of the SNPs associ-
ated with A42 levels survived correction for multiple
testing.
For MMSE, the minor C allele of another SNP,
rs7536292, was nominally associated with higher
MMSE scores, but this association did not remain
significant after multiple testing correction. None of
the SNPs were associated with T-tau or P-tau, neither
before nor after correction. This would be logical as
unaltered P-tau levels has been reported in Sort1(-/-)
mice crossed with an AD model strain [54].
When comparing with previous studies, all SNPs
have previously been analyzed in different AD pop-
ulations, in relation to sAD [55–59], fAD [36], or
dementia [60]. In the latter study, Reynolds et al.
found rs17585335 to be nominally associated with
risk of dementia, but the authors concluded that
the association was not convincing enough [60].
Zeng et al. investigated a possible association of
SORT1 and AD in a Han Chinese population where
none of the tested SNPs showed any significant result
[56]. Indeed, two of the SNPs in the study (rs646776
and rs464218) were also included in our study, con-
firming no associations with AD. On the other hand,
the SNP rs17646665 that our study highlighted as
strongly associated with a lower risk of AD, was not
included in theirs and this SNP shows a very low
LD to the tested SNPs in the Han Chinese study,
which might explain the negative outcome. Addition-
ally, we assume that a genetic variation may exist
between cohorts from different regions, i.e., when
comparing Han Chinese and European Caucasians.
Moreover, rs17646665 has previously been included
in a large scale study where several members of
the VPS10P domain receptors family were tested
for association with AD [55], but no associations
were found for rs17646665 in this study or in pre-
vious GWAS analyses [57–59]. Due to differences in
reported studies and our material, it is possible that
the association in our cohort could be restricted to a
Swedish/Scandinavian population.
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CVD and serum lipid levels are two of the major
risk factors for developing AD [61], and as previously
described, SORT1 has been shown to be associated
with both serum lipid levels and CVD. In other words,
SORT1 might play an important role in explaining the
underlying relation between CVD, serum lipid levels,
and AD. In the present study, we have indeed found
an association between SORT1 and the risk of AD. To
expand our knowledge in this field, we need to further
investigate how SORT1 is linked to the disease by
exploring underlying mechanisms. We suggest that
future research will explore measurements of AD
CSF biomarkers in combination with biomarkers for
CVD and serum lipid levels, since this combined may
generate useful information and knowledge regarding
the link between CVD and AD, which would be ben-
eficial for future drug development. We also suggest
that pharmacological tools that modulate the uptake
and clearance of apoE-A-sortilin complexes could
serve as future therapeutics for AD.
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